

- for Lambert-Eaton myasthenic syndrome, 2703
- for myasthenia gravis, 2704
- for orthostatic hypotension, 146, 2644
- Pyridoxal 5'-phosphate (PLP), 426e-5
- Pyridoxine (vitamin B₆), **96e-4**
- for acral erythema, 380
- for alcohol-induced acidosis, 64e-9, 319
- deficiency of. *See* Pyridoxine (vitamin B₆) deficiency
- dietary sources of, 96e-4
- drug interactions of, 205e-3
- functions of, 96e-2f, 96e-4
- for isoniazid toxicity, 473e-12t, 1116, 2690
- for nausea and vomiting in pregnancy, 261
- parenteral requirement for, 98e-5t
- recommended intake of, 95e-2t
- reference range for, 2766t
- for sideroblastic anemia, 2531
- structure of, 96e-2f
- for TB prophylaxis in HIV infection, 1251t
- toxicity of, 96e-5, 463t, 2687-2688, 2687t
- for tuberculous meningitis, 899
- Pyridoxine (vitamin B₆) deficiency
- atherosclerosis in, 290e-2
- clinical features of, 96e-1t, 360
- dietary level associated with, 96e-1t, 96e-4
- neuropathy in, 2690
- Pyridoxine-dependent seizures, 434e-3t
- Pyrilamine, 473e-8t
- Pyrimethamine
- action of, 246e-12
- adverse effects of, 246e-4t, 246e-12, 647, 1380t, 1384
- for *C. belli* infections, 1407
- for CNS toxoplasmosis, 903
- drug interactions of, 246e-4t
- for malaria, 1378t, 1380t
- for PCP prophylaxis, 1251t, 1362t
- pharmacology of, 246e-12, 1380t
- in pregnancy and lactation, 246e-4t
- resistance to, 1384
- for toxoplasmosis, 1404
- for toxoplasmosis prophylaxis, 1251-1252t, 1404
- Pyrimidine-5'-nucleotidase (P5N) deficiency, 431e-5t, 431e-6f, 654t, 657
- Pyrimidine-5'-nucleotidase (P5N) superactivity, 431e-5t
- Pyrimidine metabolism
- inborn errors of, 431e-5t, 431e-6
- medication effects on, 431e-6
- schematic of, 431e-6f
- PYRIN domains, 422, 2212-2213
- Pyrin protein, 372e-8t, 2212
- Pyrogens, 124
- Pyroglutamic acid, 320
- Pyronaridine, 246e-6t, 246e-12
- Pyroptosis, 1234
- Pyrosis. *See* Heartburn
- Pyrroles, 205e-7
- Δ-Pyrroline-5-carboxylate synthase deficiency, 434e-3t
- Pyruvate dehydrogenase complex (PDC), 372e-24t, 2060
- Pyruvate dehydrogenase kinase (PDK), 102e-13
- Pyruvate kinase deficiency, 281, 433e-2t, 650f, 653-654, 654t
- 6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency, 434e-2t
- Pyuria, 294
- Q
- Q fever
- acute, 1155t, 1161
- chronic, 1162
- clinical features of, 137, 152e-3t, 1561
- diagnosis of, 1162
- epidemiology of, 1155t, 1161
- etiology of, 1155t, 1161
- fatigue syndrome following, 1161
- global considerations in, 1161
- incubation period for, 152e-3t
- prevention of, 152e-3t, 1162
- in returning war veterans, 152e-3t, 152e-8
- treatment of, 152e-3t, 1162
- Q fever vaccine, 1162
- QRS complex, 273e-1, 1451, 1452-1453, 1453f
- QRS voltage, low, 1457, 1459f
- QT interval
- prolonged, 41, 307, 313, 315, 1457, 1458f
- shortened, 1457
- variability, 273e-5
- Quadrantanopia, 198f
- Quadripareisis, 157, 157t
- Quadruplegic fever, 2660
- Quad screen, 83e-4
- Quality in health care, **12e-2**
- data about current state of, 12e-3
- factors relating to, 12e-3
- national state of measurement of, 12e-3-4
- pay-for-performance and, 12e-4
- public reporting of, 12e-4
- quality theory, 12e-2-3
- racial/ethnic disparities and, 16e-1
- strategies for improving, 12e-3
- "Quality of life" issues, 5
- Quality theory, 12e-2-3
- Quantitative sudomotor axon reflex test, 2640, 2641t
- Quaranfil virus, 1310t
- Quarantaviruses, 1305, 1310t
- Quartan malarial nephropathy, 1375
- Queensland tick typhus, 1157
- Quetiapine
- adverse effects of, 2722t
- for bipolar disorder, 2718
- for delirium, 64, 64t
- for dementia, 175-176
- overdosage/poisoning with, 473e-8t
- for psychosis in Huntington's disease, 2622
- for psychosis in PD, 2617
- for schizophrenia, 2721, 2722t
- Quinacrine
- action of, 246e-12
- adverse effects of, 246e-6t, 279, 379
- drug interactions of, 246e-1t, 246e-6t
- pharmacology of, 246e-12
- in pregnancy and lactation, 246e-6t
- for SLE, 2132
- Quincke's pulsations, of nailbed, 51e-5, 1535
- Quinidine
- action of, 273e-6t
- adverse effects of
- arthralgias, 2218t
- cardiac, 246e-13
- common/frequent, 246e-6t, 1379, 1380t
- cutaneous, 353
- fever, 138
- lupus syndrome, 2218t
- nonarrhythmic, 1480t
- occasional, 246e-6t
- proarrhythmic, 1379, 1480t
- rare, 1380t
- renal, 246e-13
- thrombocytopenia, 44, 727t
- for arrhythmias, 1479t, 1480t, 1498
- dosage of, 1479t, 1480t
- drug interactions of, 34t, 42, 42t, 43, 246e-6t
- azoles, 246e-3t
- mefloquine, 246e-10
- SSRIs, 2711t
- for malaria, 780t, 1378t, 1379, 1380t
- metabolism of, 34t
- pharmacology of, 246e-13, 1380t, 1479t, 1480t
- in pregnancy and lactation, 246e-6t
- therapeutic monitoring of, 2765t
- Quinine
- action of, 246e-13
- adverse effects of
- common/frequent, 246e-6t, 1380t
- occasional, 246e-6t
- oral pigmentation, 240t
- rare, 1380t
- renal, 246e-13
- thrombocytopenia, 44, 727, 727t, 729
- thrombotic thrombocytopenic purpura, 1864
- for *Babesia* infection, 780t, 1386-1387, 1386t
- drug interactions of, 246e-6t, 246e-10, 246e-13
- for malaria, 780t, 1380t
- overdosage/poisoning with, 473e-13t
- pharmacology of, 246e-13
- in pregnancy and lactation, 246e-6t
- Quinolones
- action of, 931t, 932, 932f
- adverse effects of, 2218t
- overdosage/poisoning with, 473e-13t
- resistance to, 931t, 934, 962, 1004
- for travelers' diarrhea, 796-797
- Quinsy. *See* Peritonsillar abscess
- Quintan fever. *See* Trench fever
- 3-Quinuclidinyl benzilate, 262e-1t
- Quinupristin-dalfopristin
- action of, 931-932, 931t, 944, 961
- adverse effects of, 938t, 944, 976
- drug interactions of, 939t, 944
- for enterococcal infections, 975t, 976
- indications for, 941t, 944
- metabolism of, 935
- for MRSA infections, 961, 962t
- in pregnancy and lactation, 937t
- resistance to, 931t, 934, 941t
- Quorum sensing, 1062
- Q wave
- characteristics of, 1451
- in myocardial infarction, 1456
- anterior, 269e-4f, 269e-7f, 1456f
- anteroseptal, 269e-5f
- inferior, 269e-8f, 1456f
- variability, 1457f, 1600
- R
- R0 (reproduction number), 778
- R5 viruses, 1235
- R5X4 viruses, 1235
- R207910 (bedaquiline), 205e-7
- RA. *See* Rheumatoid arthritis (RA)
- RAA system. *See* Renin-angiotensin-aldosterone (RAA) system
- Rabeprazole
- adverse effects of, 1921
- for GERD, 263
- for peptic ulcer disease, 1920, 1920t
- for ZES, 1929
- Rabies, **1299**
- clinical features of, 896, 1301-1302, 1302f, 1302t
- diagnosis of, 152e-2t, 896, 1302, 1302f
- differential diagnosis of, 896, 1303
- epidemiology of, 1300, 1300f
- global considerations in, 1300
- incubation period for, 152e-2t
- pathogenesis of, 145e-1, 1300-1301, 1301f
- postexposure prophylaxis for, 167e-3, 167e-3t, 1303-1304, 1303f
- preexposure vaccination for, 1304
- prevention of, 152e-2t
- prognosis of, 1303
- in returning war veterans, 152e-2t, 152e-7
- treatment of, 1303
- Rabies immune globulin, 167e-3, 1303
- Rabies vaccine
- after bite-wounds, 167e-3
- Guillain-Barré syndrome and, 2695
- postexposure, 1304
- preexposure, 1304
- for travelers, 795t, 796, 1304
- Rabies virus, 1299
- Raccoon pinworm. *See* *Baylisascaris procyonis* infections
- Raccoon sign, 457e-2, 721, 721f
- "Rachitic rosary," 2466
- Racial/ethnic disparities in health care, **16e-1**
- clinical decision-making and, 16e-4
- health system interventions for, 16e-5
- implications for clinical practice, 16e-6-7
- mistrust and, 16e-4-5, 16e-6-7
- nature and extent of, 16e-1-2
- patient interventions for, 16e-6
- provider interventions for, 16e-5-6
- provider-patient communication and, 16e-3-4, 16e-4f